Allergan Granted Marketing Authorization by the FDA for TrueTear™, the First Intranasal Neurostimula
Results of the first phase 3 trial in this field were announced.
Okogen, Inc. to present at 2017 Biotech Showcase
How this particular type of gene editing works and a discussion of its potential uses in the future.
Ophthalmic Product Development Insights
Second Disease Indication Shows Versatility of Paracrine Signaling Solution
Like death and taxes, presbyopia is one of life’s certainties, an inevitable companion to the aging process
A look at ocular/nasal interactions and how they can affect our pharmaceutical therapies.
Early detection may allow treatment, and possibly reversal. Part 2 of a two-part series.